• Save
NEWS

Lupin and Aptissen announce exclusive distribution agreement of Synolis VA for Canada

Lupin and Aptissen announce exclusive distribution agreement of Synolis VA for Canada

Lupin and Aptissen announce exclusive distribution agreement of Synolis VA for Canada
  • Save

Mumbai, Geneva, Montreal, May 09, 2019: Lupin Limited (#Lupin) and Aptissen S.A. (#Aptissen) announced that they have entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute and sell the current Aptissen products in Canada. This includes immediate rights to distribute Synolis VA for the treatment of Osteoarthritis. Based on Statistics Canada, Osteoarthritis affects more than 10% of Canadians aged 15 or older.

Synolis VA (Visco-Antalgic) is the intra-articular injection product for osteoarthritis with a unique combination of Hyaluronic Acid and high concentration of Sorbitol. Synolis VA 40/80 is already approved by Health Canada and an additional strength is currently under review.

Commenting on this development, Dr. Sofia Mumtaz, President of Lupin Pharma Canada stated, “We are pleased to partner with Aptissen for marketing and distribution of Synolis VA, a branded product in Canada. This partnership helps us expand our product portfolio in the Canadian market. We remain committed to bring superior medical products and leverage our distribution strength to allow easy access to specialty medicines in the market.” Read More

152total visits,3visits today

0 Shares
Market King
I am a investor and Technical analysis.

Leave a Reply